Dana McGinty, MD
Internal Medicine · Washington, DCNPI 1639195605
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,175 of the $46,825 with a category attached, or 75.1%. AbbVie accounts for 80.1% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2020 at $17,108 and has fallen 69.1% since, to $5,291 in 2025. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 616 payments — averaging $76.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$37K
- AstraZeneca$2K
- Novo Nordisk$881
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$851
- Otsuka America Pharmaceutical, Inc.$823
- Boehringer Ingelheim$661
- plus $5K from 30 others
What the payments were for
- Speaking & faculty fees$35,17575%
- Travel & lodging$3941%
- Food & beverage$11,21924%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 148 | $37,495 |
| AstraZeneca | 80 | $1,531 |
| Novo Nordisk | 55 | $881 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $851 |
| Otsuka America Pharmaceutical, Inc. | 38 | $823 |
| Boehringer Ingelheim | 24 | $661 |
| Pfizer | 34 | $640 |
| Lilly USA, LLC | 26 | $585 |
| Lundbeck LLC | 17 | $415 |
| Merck | 20 | $370 |
| Sunovion Pharmaceuticals Inc. | 20 | $368 |
| Abbott | 21 | $338 |
| Novartis | 15 | $264 |
| GSK | 11 | $256 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $171 |
| Alkermes, Inc. | 2 | $133 |
| Sanofi-aventis U.S. LLC | 6 | $117 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $110 |
| Bayer | 4 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Gilead | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $63 |
| Hikma Pharmaceuticals USA | 4 | $61 |
| Astellas Pharma US Inc | 3 | $57 |
| Amgen | 3 | $55 |
| MDD US Operations, LLC | 2 | $51 |
| Acerus Pharmaceuticals Corporation | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $48 |
| Aytu Biopharma, Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Clarus Therapeutics Inc. | 2 | $22 |
| Eisai Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,825 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $133,560 |
| JardianceEmpagliflozin | 52 | $63,441 |
| MounjaroTirzepatide | 43 | $61,906 |
| EliquisApixaban | 34 | $51,632 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $45,818 |
| VraylarCariprazine Hcl | 17 | $37,493 |
| LinzessLinaclotide | 21 | $25,851 |
| RybelsusSemaglutide | 15 | $24,115 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $7,296 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,369 |
| Novolog FlexpenInsulin Aspart | 12 | $3,287 |
| Fluocinonide | 32 | $2,522 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 50 | $2,185 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 24 | $1,977 |
| Gabapentin | 71 | $1,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $881 | $157,675110 claims |
| Boehringer IngelheimJardiance | $661 | $63,44152 claims |
| AbbVieVraylar, Linzess | $37,495 | $63,34438 claims |
| Lilly USA, LLCMounjaro | $585 | $61,90643 claims |
| PfizerEliquis | $640 | $51,63234 claims |
| GSKTrelegy Ellipta | $256 | $45,81849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 645 internal medicine providers in District of Columbia.
Other internal medicine in Washington
- Andrea SingerWashington$850K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$233K
- Geoffrey GibneyWashington$185K
- Kevin GriffithsWashington$180K
- Bruce RashbaumWashington$86K
- Jessica Wang-MemoliWashington$56K
- Geeta NayyarWashington$46K
- Marie BorumWashington$42K
- Ali KhanWashington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.